CN114401735A - 抗微生物的、细菌噬菌体来源的多肽及其针对革兰氏阴性和抗酸细菌的用途 - Google Patents

抗微生物的、细菌噬菌体来源的多肽及其针对革兰氏阴性和抗酸细菌的用途 Download PDF

Info

Publication number
CN114401735A
CN114401735A CN202080062511.XA CN202080062511A CN114401735A CN 114401735 A CN114401735 A CN 114401735A CN 202080062511 A CN202080062511 A CN 202080062511A CN 114401735 A CN114401735 A CN 114401735A
Authority
CN
China
Prior art keywords
seq
gram
species
bacteria
chp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080062511.XA
Other languages
English (en)
Chinese (zh)
Inventor
R·舒赫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Contrafect Corp
Original Assignee
Contrafect Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contrafect Corp filed Critical Contrafect Corp
Publication of CN114401735A publication Critical patent/CN114401735A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14211—Microviridae
    • C12N2795/14222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080062511.XA 2019-07-05 2020-07-02 抗微生物的、细菌噬菌体来源的多肽及其针对革兰氏阴性和抗酸细菌的用途 Pending CN114401735A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962870908P 2019-07-05 2019-07-05
US62/870908 2019-07-05
US201962892783P 2019-08-28 2019-08-28
US62/892783 2019-08-28
US201962911900P 2019-10-07 2019-10-07
US62/911900 2019-10-07
US201962948052P 2019-12-13 2019-12-13
US62/948052 2019-12-13
US202062964743P 2020-01-23 2020-01-23
US62/964743 2020-01-23
PCT/US2020/040714 WO2021007107A1 (en) 2019-07-05 2020-07-02 Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria

Publications (1)

Publication Number Publication Date
CN114401735A true CN114401735A (zh) 2022-04-26

Family

ID=74114204

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080062511.XA Pending CN114401735A (zh) 2019-07-05 2020-07-02 抗微生物的、细菌噬菌体来源的多肽及其针对革兰氏阴性和抗酸细菌的用途

Country Status (11)

Country Link
US (1) US20220401514A1 (https=)
EP (1) EP3993821A4 (https=)
JP (1) JP2022539383A (https=)
KR (1) KR20220029746A (https=)
CN (1) CN114401735A (https=)
AU (1) AU2020310107A1 (https=)
BR (1) BR112021025948A2 (https=)
CA (1) CA3145990A1 (https=)
IL (1) IL289412A (https=)
MX (1) MX2021015563A (https=)
WO (1) WO2021007107A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210330738A1 (en) * 2018-03-29 2021-10-28 Contrafect Corporation Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
EP3902457A1 (en) * 2018-12-27 2021-11-03 Johnson & Johnson Consumer Inc. Device and method for selective application of topical composition using dynamic threshold values
WO2022032273A1 (en) 2020-08-03 2022-02-10 Johnson & Johnson Consumer Inc. System and method for selective application of cosmetic composition to impart undereye brightening
WO2022204280A1 (en) * 2021-03-26 2022-09-29 Contrafect Corporation Amurins lysins, and lysin-antimicrobial peptide (amp) constructs active against gram-negative bacteria
CN121445856A (zh) * 2025-10-24 2026-02-03 中国农业科学院生物技术研究所 溶菌酶及其衍生的抗菌肽和在制备抑菌药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741697A (en) * 1995-11-30 1998-04-21 University Of Rochester Bacteriophage of chlamydia psittaci
US20050142547A1 (en) * 2001-05-23 2005-06-30 Robert Brunham Diagnosis of vascular disease susceptibility using bacteriophage phi-cpn1 host chlamydia

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2445515T3 (en) * 2009-06-26 2016-07-04 Univ Leuven Kath antimicrobial agents
CN112368376A (zh) * 2018-03-29 2021-02-12 康特拉费克特公司 溶素-抗微生物肽(amp)多肽构建体、溶素、其分离的编码多核苷酸及其用途
US20210330738A1 (en) * 2018-03-29 2021-10-28 Contrafect Corporation Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
WO2020046747A1 (en) * 2018-08-23 2020-03-05 Contrafect Corporation Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741697A (en) * 1995-11-30 1998-04-21 University Of Rochester Bacteriophage of chlamydia psittaci
US20050142547A1 (en) * 2001-05-23 2005-06-30 Robert Brunham Diagnosis of vascular disease susceptibility using bacteriophage phi-cpn1 host chlamydia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
B. L. LIU等: "Molecular Characterization of a Bacteriophage (Chp2) from Chlamydia psittaci", JOURNAL OF VIROLOGY, vol. 74, no. 8, pages 3465 *

Also Published As

Publication number Publication date
US20220401514A1 (en) 2022-12-22
JP2022539383A (ja) 2022-09-08
WO2021007107A1 (en) 2021-01-14
CA3145990A1 (en) 2021-01-14
BR112021025948A2 (pt) 2022-02-08
EP3993821A4 (en) 2023-07-19
EP3993821A1 (en) 2022-05-11
MX2021015563A (es) 2022-03-17
AU2020310107A1 (en) 2022-01-20
IL289412A (en) 2022-02-01
KR20220029746A (ko) 2022-03-08

Similar Documents

Publication Publication Date Title
US20240018192A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
US20210147498A1 (en) Use of gram-negative lysin-antimicrobial peptide (amp) polypeptide constructs in pulmonary surfactant and biofilms
US20220402984A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
CN114401735A (zh) 抗微生物的、细菌噬菌体来源的多肽及其针对革兰氏阴性和抗酸细菌的用途
US20210330738A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
US20240181022A1 (en) Amurins lysins, and lysin-antimicrobial peptide (amp) constructs active against gram-negative bacteria
US20220411473A1 (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof
CN117377680A (zh) 针对革兰氏阴性细菌有活性的amurin溶素和溶素-抗微生物肽(AMP)构建体
RU2804774C2 (ru) Происходящие из бактериофагов противомикробные полипептиды и их применение против грамотрицательных бактерий

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220426

WD01 Invention patent application deemed withdrawn after publication